Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02401893 |
Recruitment Status :
Completed
First Posted : March 30, 2015
Last Update Posted : March 30, 2015
|
Sponsor:
Vanderbilt University
Collaborators:
Centers for Disease Control and Prevention
Marshfield Clinic Research Foundation
Information provided by (Responsible Party):
Keipp Talbot, Vanderbilt University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Little is known about factors associated with maintenance of hemagglutinin inhibition (HAI) antibodies after influenza vaccination in older adults so the investigators enrolled adults ≥50 years.
Condition or disease | Intervention/treatment |
---|---|
Aging | Biological: Influenza Vaccine |

Study Type : | Observational |
Actual Enrollment : | 510 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults |
Study Start Date : | September 2009 |
Actual Primary Completion Date : | July 2010 |
Actual Study Completion Date : | January 2014 |
Resource links provided by the National Library of Medicine

Drug Information available for:
Influenza Vaccines
Intervention Details:
- Biological: Influenza Vaccine
Everyone immunized as recommended by current guidelines
Primary Outcome Measures :
- Maintenance of Immune Response using Hemagglutinin inhibition titers [ Time Frame: 1 year ]
Biospecimen Retention: Samples With DNA
serum samples were collected
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Study Population
Subjects were enrolled at Vanderbilt University Medical Center and Marshfield Clinic Research Foundation during September and October 2009. Subjects were eligible for recruitment if they were ≥50 years of age and had no previous allergy or reaction to influenza vaccination.
Criteria
Inclusion Criteria:
- Age >=50 years
Exclusion Criteria:
- Prior vaccine allergy or history of guillain barre
No Contacts or Locations Provided
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Keipp Talbot, Assistant Professor, Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT02401893 |
Other Study ID Numbers: |
Serum 2009 |
First Posted: | March 30, 2015 Key Record Dates |
Last Update Posted: | March 30, 2015 |
Last Verified: | March 2015 |
Keywords provided by Keipp Talbot, Vanderbilt University:
aging influenza vaccine immune responses |
Additional relevant MeSH terms:
Influenza, Human Respiratory Tract Infections Infections Orthomyxoviridae Infections |
RNA Virus Infections Virus Diseases Respiratory Tract Diseases |